Biologics for hidradenitis suppurativa: evolution of the treatment paradigm
Introduction Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high
unmet need for effective medical management. Clinically, it is characterized by inflammatory …
unmet need for effective medical management. Clinically, it is characterized by inflammatory …
Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data
F Martora, M Scalvenzi, T Battista… - Clinical, Cosmetic …, 2023 - Taylor & Francis
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …
[[Artículo traducido]] Revisión narrativa y actualización en fármacos biológicos y de pequeña molécula para el tratamiento de la hidradenitis supurativa: una entidad …
M Mansilla-Polo, B Escutia-Muñoz… - Actas Dermo …, 2023 - Elsevier
La hidradenitis supurativa (HS) es una entidad inflamatoria crónica caracterizada por la
aparición de múltiples nódulos, abscesos y fístulas, de predominio en regiones apocrinas …
aparición de múltiples nódulos, abscesos y fístulas, de predominio en regiones apocrinas …
Emerging treatments and the clinical trial landscape for hidradenitis suppurativa part I: topical and systemic medical therapies
Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with
painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part …
painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part …
Secukinumab in Hidradenitis Suppurativa patients who failed Adalimumab: A 52-week real-life study
F Martora, C Marasca, S Cacciapuoti… - Clinical, Cosmetic …, 2024 - Taylor & Francis
Background The treatment of hidradenitis suppurativa (HS) has always been a real
challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is …
challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is …
Hidradenitis suppurativa in children and adolescents: an update on pharmacologic treatment options
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that
manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin …
manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin …
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
V Navarro-Compán, L Puig, S Vidal, J Ramírez… - Frontiers in …, 2023 - frontiersin.org
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F);
sequence homology is highest between IL-17A and IL-17F, displaying certain overlap** …
sequence homology is highest between IL-17A and IL-17F, displaying certain overlap** …
Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors
Hidradenitis suppurativa (HS) is a chronic, relapsing, and debilitating inflammatory skin
disease with a profound impact on health-related quality of life. 1, 2 The disease burden of …
disease with a profound impact on health-related quality of life. 1, 2 The disease burden of …
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation
Hidradenitis suppurativa is a chronic inflammatory skin disease with limited treatment
options. The poorly understood pathogenesis hinders the development of effective …
options. The poorly understood pathogenesis hinders the development of effective …
Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17/IL-23 axis in patients with Hidradenitis Suppurativa
Background Paradoxical psoriasis (PP) has been mainly described in patients receiving
tumor necrosis factor-α (TNFα)-inhibitors for inflammatory bowel disease or psoriasis …
tumor necrosis factor-α (TNFα)-inhibitors for inflammatory bowel disease or psoriasis …